Boston Scientific has commenced the AVANT GUARD clinical trial of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line treatment for persistent atrial fibrillation.
The first trial subject was enrolled at the Cleveland Clinic in the US.
AVANT GUARD will evaluate the safety and effectiveness of the system, marking the launch of the only trial to assess PFA as a frontline therapy in people with this type of AF.
